NIH

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge, Bettina B. Hoeppner, Cristina Cusin, Dawn F. Ionescu, Sanjay J. Mathew, Lee C. Chang, Dan V. Iosifescu, James Murrough, Charles Debattista, Alan F. Schatzberg, Madhukar H. Trivedi, Manish K Jha, Gerard Sanacora, Samuel T. Wilkinson, and George I. Papakostas Published 3 October 2018 | doi: 10.1038/s41380-018-0256-5 …

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) Read More »

Ketamine and Depression: From Despair to Hope in Hours

Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).